Company intelligence / Profile preview

Celmatix

New York, New York, United States

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Celmatix is a preclinical-stage biotech leveraging proprietary multi-omics insights into ovarian biology for novel therapies targeting ovarian aging, infertility, endometriosis, and PCOS; lead AMHR2 agonist candidate (ovarian aging) has shown protective effects in animal models against chemotherapy-induced ovarian decline, and programs are advancing rapidly with government (ARPA-H) support

Therapeutic areas: Women's HealthEndocrinology
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

2 assets

JNK-IN-8

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Advanced Research Projects Agency for Health (ARPA-H) (U.S. government strategic partnership via SPARK contract)Reproductive Medicine Associates (data collaboration, past)

Beyond the preview

Go deeper on Celmatix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celmatix.

Explore the full profile